Iran to Present Cellular Medicine for Bone Marrow Transplant Patients by Winter
“This drug belongs to the category of advanced medical treatment products (ATMPs). These products containing allogeneic mesenchymal cells derived from the placenta and fetal membranes are used for GvHD (graft-versus-host disease),” said Nasser Aqdami, the managing director of the knowledge-based company.
Noting that the development of the production technology of this cellular drug was carried out by Dr. Behnam Sadeqi, an Iranian researcher in the laboratory of the University of Sweden, he said, “We also developed this technology in our company, and after the final testing process, the mass production of this cellular drug started, and we hope it will enter the country's pharmaceutical market by winter.”
“Studies have shown that this cell drug controls or cures the disease in more than 60% of cases, and in 100% of cases, it reduces symptoms and saves the patient from death,” Aqdami said.
GvHD is a severe complication that can occur following hematopoietic stem cell transplantation. This condition arises when immunocompetent T lymphocytes from the donor graft recognize the recipient's tissues as foreign due to histocompatibility differences and initiate an immune response against them.
This attack typically occurs within the first 100 days posttransplant, leading to tissue damage in various organs, including the skin, gastrointestinal tract, liver, and lungs. GVHD can manifest as acute or chronic forms, each with distinct clinical presentations and management strategies.
4155/v
